News
ATXS
10.48
-0.57%
-0.06
Weekly Report: what happened at ATXS last week (0408-0412)?
Weekly Report · 4d ago
Astria Therapeutics Inc: Initial statement of beneficial ownership of securities
Press release · 04/09 14:03
Astria Therapeutics Expands Board, Appoints New Director
TipRanks · 04/09 12:22
ASTRIA THERAPEUTICS INC - ON APRIL 5, BOARD INCREASED SIZE OF BOARD FROM EIGHT TO NINE DIRECTORS
Reuters · 04/09 12:08
*Astria Therapeutics Appoints Sunil Agarwal to Its Bd of Directors
Dow Jones · 04/09 12:01
ASTRIA THERAPEUTICS APPOINTS SUNIL AGARWAL TO ITS BOARD OF DIRECTORS
Reuters · 04/09 12:00
Weekly Report: what happened at ATXS last week (0401-0405)?
Weekly Report · 04/08 11:13
ASTRIA THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 04/03 20:10
Weekly Report: what happened at ATXS last week (0325-0329)?
Weekly Report · 04/01 11:11
Astria Therapeutics Is Maintained at Outperform by Wedbush
Dow Jones · 03/26 13:44
Astria Therapeutics Price Target Raised to $22.00/Share From $17.00 by Wedbush
Dow Jones · 03/26 13:44
Wedbush Maintains Outperform on Astria Therapeutics, Raises Price Target to $22
Benzinga · 03/26 13:34
Wedbush Remains a Buy on Astria Therapeutics (ATXS)
TipRanks · 03/26 12:15
Astria Therapeutics Is Maintained at Buy by Jefferies
Dow Jones · 03/26 11:29
Astria Therapeutics Price Target Raised to $27.00/Share From $22.00 by Jefferies
Dow Jones · 03/26 11:29
Buy Recommendation for Astria Therapeutics Backed by Promising ALPHA-STAR Trial Results
TipRanks · 03/26 10:45
Notable Monday Option Activity: ATXS, UWMC, SMTC
NASDAQ · 03/25 19:30
Buy Rating Affirmed for Astria Therapeutics on Promising STAR-0215 Data and Market Potential
TipRanks · 03/25 18:05
Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY) and Astria Therapeutics (ATXS)
TipRanks · 03/25 16:50
Astria Therapeutics Price Target Maintained With a $18.00/Share by HC Wainwright & Co.
Dow Jones · 03/25 16:45
More
Webull provides a variety of real-time ATXS stock news. You can receive the latest news about Astria Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ATXS
Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis (AD). The Company owns two patent families directed to STAR-0215. The first patent family is directed to the composition of matter of its product candidate STAR-0215 and its use in treating various plasma kallikrein associated disorders including HAE. In the second patent family, the Company owns one International (PCT) patent application directed to methods of treating various plasma-kallikrein associated disorders, including HAE, with specific dosing regimens of the STAR-0215 antibody.